KB707

AXP000196.1 · Viral vector gene therapy

Platform
HSV-1 (replication-defective)
Originator
Krystal Biotech
Sponsor
Krystal Biotech

Names

NameTypeSource
KB707preferred name, codecurator, press
KYANITE-1 ambiguoussynonympress
OPAL-1 ambiguoussynonympress

Virus

Role
In vivo gene transfer
Family
Herpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
non replicating
Modifications
replication-incompetent HSV-1 backbone; human IL-12 and IL-2 cassettes
Transgenes
IL12A, IL12B, IL2
Route
intratumoral, inhaled
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06228326A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsRecruitingPhase 1/22024-04-172027-02250Advanced Cancer; Lung Cancer (NSCLC); Lung Cancer Metastatic; Lung Cancer, Non-small Cell; Solid Tumor, Adult
NCT05970497A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/22023-10-312027-07240Cancer; Cutaneous Melanoma; Melanoma Stage III; Melanoma Stage IV

Recent changes

No changes recorded in its trials yet.

Notes

Replication-incompetent HSV-1 vector delivering human IL-12 and IL-2 to tumours; given intratumorally (phase 1 OPAL-1, NCT05970497) and by inhalation for lung tumours and pulmonary metastases (phase 1 KYANITE-1, NCT06228326). FDA fast track for both routes. Recorded as in_vivo_gene_transfer, not oncolytic: the vector does not replicate.

How to cite

KB707 (AXP000196.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000196.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.